These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20187228)

  • 1. Inflammation and Parkinson's disease pathogenesis.
    Przedborski S
    Mov Disord; 2010; 25 Suppl 1():S55-7. PubMed ID: 20187228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inflammation and Parkinson's disease].
    Barcia González C; Herrero Ezquerro MT
    Rev Neurol; 2004 Mar 16-31; 38(6):545-53. PubMed ID: 15054720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
    Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
    Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
    Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC
    Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease.
    Yang X; Song L; Liu Z
    Neuroreport; 2010 Mar; 21(4):268-72. PubMed ID: 20087233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and neurodegeneration in Parkinson's disease.
    McGeer PL; McGeer EG
    Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S3-7. PubMed ID: 15109580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of inflammation in the pathogenesis of Parkinson's disease: models, mechanisms, and therapeutic interventions.
    Hong JS
    Ann N Y Acad Sci; 2005 Aug; 1053():151-2. PubMed ID: 16179518
    [No Abstract]   [Full Text] [Related]  

  • 10. Inflammation in Parkinson's disease.
    Wüllner U; Klockgether T
    J Neurol; 2003 Feb; 250 Suppl 1():I35-8. PubMed ID: 12761634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
    Hald A; Lotharius J
    Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
    Kurkowska-Jastrzebska I; Litwin T; Joniec I; Ciesielska A; Przybyłkowski A; Członkowski A; Członkowska A
    Int Immunopharmacol; 2004 Oct; 4(10-11):1307-18. PubMed ID: 15313429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroinflammatory processes in Parkinson's disease.
    Hunot S; Hirsch EC
    Ann Neurol; 2003; 53 Suppl 3():S49-58; discussion S58-60. PubMed ID: 12666098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating inflammation in childhood neurodegenerative disorders.
    Lim M
    Dev Med Child Neurol; 2011 Apr; 53(4):298-304. PubMed ID: 21309766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease.
    Okuno T; Nakatsuji Y; Kumanogoh A; Moriya M; Ichinose H; Sumi H; Fujimura H; Kikutani H; Sakoda S
    J Neurosci Res; 2005 Sep; 81(6):874-82. PubMed ID: 16041799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
    Watanabe Y; Himeda T; Araki T
    Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.